Clinical trials: Prostate Disease
Prostatic Neoplasms, Prostatic Hyperplasia
Prostate Mechanical Imager (PMI) Clinical Bridging Study
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite…
- Trial name
- PMI (NCT00822952)
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Artann Laboratories
Prostate Cancer
Evaluation of Prostate Cancer Margins
Pathological assessment of prostate tissue
- Trial name
- NCT05317143
- Testing
- Evaluation of prostate cancer margins
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Intuitive Surgical
Benign Prostatic Hyperplasia
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
Primary: Evaluate the safety and onset of symptom relief using an acute I-PSS form (7 day form). Determine onset of urinary peak flow improvement after 7 days Secondary: Determine improvement in Bother Score after 7 \& 28 days…
- Trial name
- ALF-ACUTE (NCT00540891)
- Testing
- ALFUZOSIN
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Prostate Cancer
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
- Trial name
- NCT03256630
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Genomic Health®, Inc.
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
- Trial name
- NCT05558007
- Testing
- Tadalafil 5mg, BZ371A
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Impotence, Prostate Cancer
Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
In this phase II study, an investigative (not approved by the FDA) drug called GPI 1485 is being assessed to see if it can help preserve erectile function after prostatectomy.
- Trial name
- NCT00090376
- Testing
- GPI 1485
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Spinal Cord Injuries, Enlarged Prostate With Lower Urinary Tract Symptoms
Exploratory Study Investigating Urodynamic Parameters During Catheterisation
The objective of the study is to explore and understand how urodynamic parameters are affected when emptying the bladder with an intermittent catheter.
- Trial name
- NCT03337048
- Testing
- SpeediCath
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
- Trial name
- NCT00759135
- Testing
- 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
- Where
- 30 sites in United States
- Volunteers
- 85 people
- Sponsor
- Nymox Corporation
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants…
- Conditions
- Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07488923
- Testing
- ML261
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Moonlight Bio, Inc
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Prostate Cancer Patients Treated by Radiotherapy
Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™
A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation therapy in prostate cancer patients
- Trial name
- NCT01999660
- Testing
- SpaceOAR™ implantation
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- CS Diagnostics GmbH
Prostate Cancer
Prospective Validation of Prostate Biomarkers for Repeat Biopsy
Target enrollment is 1000 prospectively enrolled subjects with an initial negative biopsy scheduled for repeat biopsy. Subjects must have had their negative index prostate biopsy procedure within 30 months of being scheduled for…
- Trial name
- PRIORITY (NCT03082274)
- Testing
- ConfirmMDx, SelectMDx
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MDx Health
Prostate Cancer
A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence
This study is designed to measure the impact of Satraplatin plus radiation therapy to the bed of the prostate in patients who have developed biochemical failure of their prostate cancer.
- Trial name
- NCT00480623
- Testing
- Satraplatin plus radiation therapy
- Where
- 4 sites in United States
- Sponsor
- Agennix
Ovarian Cancer, Breast Cancer
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior…
- Conditions
- Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer
- Trial name
- NCT04586335
- Testing
- CYH33
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Prostatic Neoplasms
PRIME - PRostate Imaging for Margin Evaluation
This study will evaluate the feasibility of using intra-operative Cerenkov Luminescence Imaging (CLI) of prostatectomy specimens to determine tumour margin status.
- Trial name
- PRIME (NCT02151097)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Lightpoint Medical Limited
Prostatic Neoplasms
Treatment Satisfaction With Ra-223 in Japan
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding…
- Trial name
- NCT03315260
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Bayer
Advanced Prostate Cancer, Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer.
- Trial name
- NCT07567846
- Testing
- GDC-1261
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 260 people
- Sponsor
- Genentech, Inc.
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
A bio-equivalence of 2 different capsule formulations in fasted subjects
- Trial name
- NCT02417831
- Testing
- tamsulosin capsules, tamsulosin HCl
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.